MetaBlok™

Potential treatment for inflammation and cancer metastasis

MetaBlok TM

MetaBlok is a new drug candidate and potential treatment for inflammation, sepsis and cancer metastasis.

Arch is currently pursuing clinical development of Metablok to prevent acute kidney injury caused by inflammationand expects...

MetaBlok and MetaMx Scientists

Lead scientists for MetaBlok™ and MetaMx™

[yjsgimgs image="images/arch_content_images/headshots/sRobbins.png" class="" title="" link="" target="" effect="none"]

Stephen Robbins

Dr. Robbins is the Scientific Director of the CIHR's Institute of Cancer Research. He is currently an Associate Professor at the University of Calgary in the Departments of...

AB569

Drug candidate for treating antibiotic resistant infections

AB569: Treatment for Drug Resistant Bacterial Infections

AB569 is a new drug candidate for treating antibiotic resistant bacterial infections, primarily in the lungs and urinary tract. It also has potential to be modified for use in...

AB569 Principal Scientist

Lead scientist for AB569 which targets Respiratory Pseudomonas Infections

[yjsgimgs image="images/arch_content_images/headshots/drHasset.png" class="" title="" link="" target="" effect="none"]

Dr. Hassett

Dr. Hassett is a Professor in the Department of Molecular Genetics, Biochemistry and Microbiology...

Arch Biopartners Enters Exclusive License Agreement With University of Cincinnati for AB569

TORONTO, ONTARIO--(Marketwired - March 16, 2016) -Arch Biopartners Inc (Arch) or (the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) announced today it has entered into an exclusive...

BORG

Peptide Solid Surface Interface

Peptide Solid Surface Interface

Arch has developed a group of novel synthetic peptides and peptide conjugates that employ a novel chemistry (non-toxic, and environmentally friendly process) to react with solid surfaces such as metals, and plastics...

BORG Peptide Solid Surface Interface Scientists

Lead scientists for BORG Peptides

[yjsgimgs image="images/arch_content_images/headshots/rIrvin.png" class="" title="" link="" target="" effect="none"]

Randall Irvin

Randall Irvin is Professor of Medical Microbiology and Immunology at the University of Alberta. He previously was a faculty...

MetaMX™

Targeting Brain Tumor Initiating Cells

Brain Tumor Initiating Cell Targeting

MetaMx™ is composed of novel, synthetic peptides that target and attach to BTICs and invasive glioma cells, for the purpose of imaging, diagnosis and developing targeted therapies to improve patient outcomes...

MetaBlok and MetaMx Scientists

[yjsgimgs image="images/arch_content_images/headshots/sRobbins.png" class="" title="" link="" target="" effect="none"]

Stephen Robbins

Dr. Robbins is the Scientific Director of the CIHR's Institute of Cancer Research. He is currently an Associate Professor at the University of Calgary in the Departments of Oncology and Biochemistry & Molecular...

    Bridging the gap between science and business

    Bringing new medical innovation to market.

    Arch Biopartners Inc. is focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. Arch works closely with the scientific community, universities and research institutions to advance and build the value of select preclinical technologies, develop the most promising intellectual...

    Investor Fundamentals

    Discover the Arch Biopartners story. Press releases, investor information, stock information, and our Reports and Filings are here.

    Management and Board of Directors

    Investor Relations and Investor Information